

Molecular follow-up of a newborn screening positive case of medium-chain acyl-coenzyme A dehydrogenase deficiency identified two ACADM variants: Are they clinically pathogenic?

Yuan-Yuan Ho, Cindy Morgan, Britt Johnson

Metabolic Genetics Clinical Area Team, Clinical Genomics Group, Invitae Corporation, San Francisco, CA

Disclosure statement: All authors are employees and stockholders of Invitae Corporation.

Introduction

Medium-chain acyl-coenzyme A dehydrogenase deficiency (MCADD) is one of the most common recessively inherited metabolic diseases and has a birth prevalence of 5.3 in 100,000 births.

MCADD is a core newborn screening (NBS) condition in all 50 states.

MCADD is caused by pathogenic mutations in the ACADM gene that affect the β -oxidation of fatty acids 6–12 carbons long.

Impaired hepatic ketogenesis in affected individuals results in hypoketotic hypoglycemia, metabolic acidosis, and liver disease. Lethargy can rapidly progress to coma and death when glycogen stores are depleted during catabolic physiological states.

If undiagnosed, MCADD has considerable morbidity and mortality.

Adverse outcomes can be prevented by avoiding metabolic stress and following simple dietary interventions.

MCADD can have a significant health impact in early life, but understanding of genotype-phenotype relationship remains limited (1).

Case

The proband is a male infant identified through NBS with a C8 level of 1.710 ($rr < 0.6$). He was 6 weeks old at the time of sample accession.

Confirmatory biochemical testing revealed continued elevation of C6, C8, C10, and C10:1 and an elevated C8/C10 ratio.

Acylglycines analysis revealed elevated hexanoylglycine with normal suberylglycine.

The proband has no known family history of MCADD, and no consanguinity was indicated.

Methods

Sequencing of the ACADM gene was the only test ordered and analysis was first performed for the proband.

Subsequent analyses were performed on the parents through Invitae's complementary variant of uncertain significance (VUS) resolution program.

Genomic DNA obtained from whole blood was enriched for targeted regions by using a hybridization-based protocol, and then sequenced with Illumina technology.

Targeted regions were sequenced with $\geq 50\times$ depth or were supplemented with additional analysis. Reads were aligned to a reference sequence (GRCh37), and sequence changes were identified and interpreted in the context of a single clinically relevant transcript, ACADM (NM_000016.5), in accordance with ACMG guidelines (2).

Enrichment and analysis focused on the coding sequence of the indicated transcripts, 10 bp of flanking intronic sequence, and other specific genomic regions demonstrated to be causative of disease at the time of assay design.

Promoters, untranslated regions, and other non-coding regions were not otherwise interrogated.

Exonic deletions and duplications were called with an in-house algorithm that determines copy number at each target by comparing the read depth for each target in the proband sequence with both mean read depth and read depth distribution obtained from a set of clinical samples (<https://www.invitae.com/en/assay/>).

The pathogenic variant identified was confirmed with Sanger sequencing.

Results and Discussion

Summary
 One Pathogenic variant and one Variant of Uncertain Significance identified in ACADM.

Clinical Summary
 ACADM: c.985A>C (p.Lys329Glu), c.793A>C (p.Asp266Gly)

- A Pathogenic variant, c.985A>C (p.Lys329Glu), and a Variant of Uncertain Significance, c.793A>C (p.Asp266Gly), were identified in ACADM. These variants are on opposite chromosomes.
- The ACADM gene is associated with medium chain acyl-CoA dehydrogenase (MCAD) deficiency (MIM:261600).
- Because MCAD is autosomal recessive, one pathogenic variant alone is insufficient as an explanation for this individual's condition and/or family history. However, the indication for testing in this individual may be consistent with disease caused by ACADM. The clinical impact of the Variant of Uncertain Significance identified in ACADM is unknown at this time. Until this uncertainty is resolved, caution should be exercised before using this result to inform clinical management decisions.
- Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCADD) is a disorder of mitochondrial fatty oxidation impairing metabolism of fatty acids 6-12 carbons in length. Affected individuals can potentially present at any age, from the neonatal period to adulthood, but most classically manifests in early childhood with fasting intolerance or decompensation during an intercurrent illness (PMID: 2032382). Biochemical findings include elevated plasma C8:10 acylcarnitines (especially C8) with elevated urinary hexanoylglycine and dicarboxylic acids or organic acid analysis (PMID: 2023395, 601867). Clinical management guidelines for MCADD may be found at: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4010000/>
- Clinical relatives (siblings, siblings and each parent) have up to a 10% chance of being a carrier of this pathogenic variant. The chance of having a child affected with autosomal recessive MCADD depends on the carrier status of the individual's partner. When two parents each carry a pathogenic variant, their chance of having an affected child is 25%. More distant relatives may also be carriers. Testing for this variant is available.
- This Variant of Uncertain Significance is not eligible for complimentary family studies as part of our VUS Resolution Program at this time, because testing other family members is unlikely to assist in variant reclassification. Please visit www.invitae.com for more information on our VUS Resolution Program.

Report Notes
 These results should be interpreted within the context of additional laboratory results, family history and clinical findings. Genetic counseling is recommended to discuss the implications of this result. For access to a network of genetic providers, please contact clinicalgenomics@invitae.com, or visit www.invitae.com or <http://med.usa.invitae.com/professionals/organizations.asp>.

Complete Table

Gene	Variant	Exon	Variant Classification
ACADM	c.985A>C (p.Lys329Glu)	Intergenic	PATHOGENIC
ACADM	c.793A>C (p.Asp266Gly)	Intronic	Uncertain Significance

The following genes were evaluated for sequence changes and exon-intron duplications:
 ACADM

Single, double, triple, and other variants were not included in this report but are available upon request.

Variant Details
 ACADM: c.985A>C (p.Lys329Glu), IntronIntergenic, PATHOGENIC
 ACADM: c.793A>C (p.Asp266Gly), IntronIntergenic, UNCERTAIN SIGNIFICANCE

- This sequence change replaces lysine with glutamic acid at codon 329 of the ACADM protein (p.Lys329Glu). The lysine residue is highly conserved and there is a small physicochemical difference between lysine and glutamic acid.
- This variant is present in population databases (rs7931234, dbSNP).
 - This variant is a known prevalent ACADM mutation (PMID: 1832306, 2224275, 2293456, 290458). It has been reported in many symptomatic MCAD deficiency patients in a homozygous state (PMID: 1832312, 2661220, 2633269, 2224275).
 - This variant is also known as p.Lys329Glu or G329E in the literature. ClinVar contains an entry for this variant (variation ID: 203546).
 - Experimental studies have shown that this variant causes a loss of enzymatic activity measured in lymphocytes from patients who are homozygous for this variant (PMID: 2020770, 2020560).
- For these reasons, this variant has been classified as pathogenic.

ACADM: c.793A>C (p.Asp266Gly), IntronIntergenic, UNCERTAIN SIGNIFICANCE

- This sequence change replaces aspartic acid with glutamine at codon 266 of the ACADM protein (p.Asp266Gly). The aspartic acid residue is weakly conserved and there is a moderate physicochemical difference between aspartic acid and glutamine.
- This variant is present in population databases (rs201375179, dbSNP).
- This variant has been reported in newborns showing biochemical markers consistent with medium chain acyl-CoA dehydrogenase (MCAD) deficiency (PMID: 19224950, 2254237, 19780256). However, it has not been reported in clinically symptomatic patients (PMID: 2032382). This sequence change is also known as p.Asp266Gly or G266E in the literature. ClinVar contains an entry for this variant (variation ID: 203546).
- Experimental studies have shown that this variant impairs the stability of the encoded enzyme and causes partial reduction of enzyme activity (NBS of wild type) (PMID: 19224950, 2023434).
- In summary this variant is a rare missense change that has been shown to partially impair protein function and has been identified in the general population as well as in individuals with the biochemical abnormalities of MCAD deficiency. However, it has not been reported in clinically symptomatic patients. For these reasons, this change has been classified as a Variant of Uncertain Significance.

The pathogenic variant p.Lys329Glu (paternal) is the most prevalent mutation in patients with clinically symptomatic MCADD. This variant is reportedly as high as 80% homozygous but is observed considerably less frequently in individuals identified through NBS (63%/47% homozygous)(3). The variant confers high risk for metabolic decompensation, although unaffected homozygous adults have been reported.

The p.Asp266Gly variant (maternal) is currently classified as a VUS. It has been previously reported in newborns with biochemical markers consistent with MCADD and shown to cause partial enzymatic deficiency (4). However, it has *not* been reported in clinically symptomatic patients.

Although this genotype has been previously described in one NBS-positive MCADD case (5), the long-term outcome is unknown.

This individual showcases the uncertain realities patients and clinicians often face when dealing with a rare disease such as MCADD for which NBS positivity with confirmatory results does not necessarily predict clinical consequences.

Conclusions

We identified two ACADM variants in trans: one pathogenic variant, p.Lys329Glu, and one VUS, p.Asp266Gly, in an MCADD infant identified through NBS. This genotype has not been reported in clinically symptomatic patients, and follow-up is needed to assess the long-term clinical outcome.

Emerging evidence supports an MCADD genotype-phenotype correlation, although further substantiation of this relationship is required.

We share this case report with the goal of contributing to MCADD genotype and phenotype data collection, which is essential for understanding the natural history of MCADD and more accurately projecting its long-term clinical consequences.

References

- Bentler K, et al., 221 newborn-screened neonates with medium-chain acyl-coenzyme A dehydrogenase deficiency: Findings from the Inborn Errors of Metabolism Collaborative. *Mol Genet Metab*. 2016 Sep; 119(1-2):75-82. doi: 10.1016/j.ymgme.2016.07.002.
- Richards S, et al., Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med*. 2015 May; 17(5):405-24. doi: 10.1038/gim.2015.50.
- Rhead WJ, Newborn screening for medium-chain acyl-CoA dehydrogenase deficiency: a global perspective. *J Inher Metab Dis*. 2006 Apr-Jun;29(2-3):370-7. DOI: 10.1007/s10545-006-0292-1.
- Jank JM, et al., The domain-specific and temperature-dependent protein misfolding phenotype of variant medium-chain acyl-CoA dehydrogenase. *PLoS One*. 2014 Apr 9;9(4):e93852. doi: 10.1371/journal.pone.0093852.
- Mauer EM, et al., Dissection of biochemical borderline phenotypes in carriers and genetic variants of medium-chain acyl-CoA dehydrogenase deficiency: implications for newborn screening [corrected]. *Clin Genet*. 2009 Aug;76(2):179-87. doi: 10.1111/j.1399-0004.2009.01217.x.